12:00 AM
Apr 22, 2013
 |  BC Week In Review  |  Company News  |  Other News

Merck KGaA musculoskeletal, pharmaceuticals news

Merck's Merck Serono S.A. unit launched the not-for-profit EspeRare Foundation to reposition existing drugs to treat rare diseases. Merck Serono will transfer the rights to rimeporide to EspeRare and also initially donate to the foundation €2.8 million ($3.7 million). EspeRare will work with patient...

Read the full 217 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >